SLC5A2 and hydrops fetalis: Numerous medications, such as beta-adrenergic receptor blockers (β-blockers), angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), angiotensin receptor–neprilysin inhibitors (ARNIs), mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter 2 (SGLT2) inhibitors, have been shown to improve cardiac function, quality of life, and survival rates in individuals with HF [3, 4].